Among adults with DownSyndrome, clinical and biological staging of AlzheimerDisease showed greater concordance compared to sporadic cases, supporting the use of cognition-based staging for clinical trial enrollment. Most discordant cases exhibited more advanced pathology than clinical stage, highlighting resilience mechanisms in this population.

This cross-sectional study examines data for participants in the Alzheimer Biomarker Consortium–Down Syndrome study to gauge the concordance of clinical and biological Alzheimer disease staging.